Biography:
Dr. Du obtained his PhD in Chinese Academy of Sciences in 2015. After he finished postdoctoral fellowships and Research Associate in the University of Maryland, Baltimore, he returned to China and be a full Professor in Shandong University. He focuses on cancer immunotherapy to dissociate the undesired immunotherapy related adverse events from the beneficial immunotherapies. April 25, 2022, the U.S. FDA has granted Fast Track designation to ONC-392, the next-gen anti-CTLA-4 monoclonal antibody (mAb) which he developed , as a single agent for the treatment of patients with metastatic NSCLC who have had disease progression on prior anti-PD-(L)1 therapy.
Title : Safe and effective immunotherapy by targeting CTLA-4